Small cell lung cancer

Niknejad, Mohammad; Danaher, Luke

doi:10.53347/rid-8586

Cited by 1 publication

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whenever clinical and radiologic suspicion for lung cancer is raised by chest radiographs, a contrast‐enhanced computed tomography (CT) scan of the chest (Figure 5A) and upper abdomen should also be performed for further evaluation. On CT scans, SCLC tumors are usually characterized as mass lesions with margins that are smooth, lobulated, or irregular and spiculated 138 . Necrosis and hemorrhage are both fairly common, as well as the bulky mediastinal nodes that conglomerate to form large masses 138 .…”

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%

“…On CT scans, SCLC tumors are usually characterized as mass lesions with margins that are smooth, lobulated, or irregular and spiculated 138 . Necrosis and hemorrhage are both fairly common, as well as the bulky mediastinal nodes that conglomerate to form large masses 138 . Rarely, SCLC tumors can also appear as solitary pulmonary nodules 138 .…”

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%

“…Necrosis and hemorrhage are both fairly common, as well as the bulky mediastinal nodes that conglomerate to form large masses 138 . Rarely, SCLC tumors can also appear as solitary pulmonary nodules 138 . Nevertheless, because of its frequent central localization, the primary tumor often cannot be visualized as a distinct entity because it merges with the nodal disease 139 .…”

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%

“…PNSs are not exclusively specific either because they can also be associated with other NE tumors, although at a much lower percentage 169 . With regard to imaging, because of its central localization and mediastinal involvement, SCLC might appear similar to lymphomas or other mediastinal tumors 138 . From a pathologic point of view, SCLC should be distinguished from large cell NE carcinoma and carcinoid tumors, NSCLC, basaloid squamous cell carcinoma, and non‐Hodgkin lymphoma 4,165 …”

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

Gay

Popper

Pirker

et al. 2023

CA A Cancer J Clinicians

112

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53 and RB1, and a high mutation burden. Because of early metastasis, only a small fraction of patients are amenable to curative‐intent lung resection, and these individuals require adjuvant platinum‐etoposide chemotherapy. Therefore, the vast majority of patients are currently being treated with chemoradiation with or without immunotherapy. In patients with disease confined to the chest, standard therapy includes thoracic radiotherapy and concurrent platinum‐etoposide chemotherapy. Patients with metastatic (extensive‐stage) disease are treated with a combination of platinum‐etoposide chemotherapy plus immunotherapy with an anti‐programmed death‐ligand 1 monoclonal antibody. Although SCLC is initially very responsive to platinum‐based chemotherapy, these responses are transient because of the development of drug resistance. In recent years, the authors have witnessed an accelerating pace of biologic insights into the disease, leading to the redefinition of the SCLC classification scheme. This emerging knowledge of SCLC molecular subtypes has the potential to define unique therapeutic vulnerabilities. Synthesizing these new discoveries with the current knowledge of SCLC biology and clinical management may lead to unprecedented advances in SCLC patient care. Here, the authors present an overview of multimodal clinical approaches in SCLC, with a special focus on illuminating how recent advancements in SCLC research could accelerate clinical development.

show abstract

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%